55. Mc Craw, D. M., Gallagher, J. R.&Harris, A. K. Characterizationofinfluenzavaccine
hemagglutinin complexes by cryo-electron microscopy and image analyses
revealsstructuralpolymorphisms.Clin.Vaccin.Immunol.23,483–495(2016).
56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor
insectandmammaliancells.Curr.Opin.Biotechnol.10,428–433(1999).
57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe
hemagglutininmoleculeof H3influenzavirusatacidicp H. Virology 126,587–599
(1983).
58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby
broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323–341
(2015).
59. Turner, H. L. etal. Potentanti-influenza H7humanmonoclonalantibodyinduces
separation of hemagglutinin receptor-binding head domains. PLo S Biol. 17,
e3000139(2019).
60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross
differentinfluenzavaccineplatformsinhumans.Nat.Commun.10,3338(2019).
61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus
epitope.Science324,246–251(2009).
62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing
allinfluenza Asubtypes. Cell 166,596–608(2016).
63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the
hemagglutininfusionmachineryoninfluenzavirions.Sci.Adv.6,eaaz8822(2020).
64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly
neutralizingantibodiesagainststructurallydistinctdomainsof H3N2HA. Vaccines
8,99(2020).
65. Richards, K. A. etal. Recombinant HA-basedvaccineoutperformssplitandsub-
unit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-
dependentantibodyresponsesinhumans.NPJVaccines5,77(2020).
66. Tay,T.etal.Investigationintoalternativetestingmethodologiesforcharacteriza-
tionofinfluenzavirusvaccine. Hum. Vaccines Immunother.11,1673–1684(2015).
67. Gallagher, J. R. et al. Characterization of hemagglutinin antigens on influenza
virus and within vaccines using electron microscopy. Vaccines https://doi.org/
10.3390/vaccines6020031(2018).
68. Public Health Agencyof Canada. Oculo-respiratorysyndromefollowinginfluenza
vaccination:reviewofpost-marketing surveillance throughfourinfluenza sea-
sonsin Canada. Can. Commun. Dis. Rep.31,217–225(2005).
69. Choudhri,Y.&Walop,W.Influenzavaccine-associatedadverseevents:resultsof
passive surveillance, Canada 2001-2002. Can. Commun. Dis. Rep. 28, 189–196
(2002).
70. Babiuk, S. etal. Aggregatecontentinfluencesthe Th 1/Th 2immuneresponseto
influenzavaccine:evidencefromamousemodel.J.Med.Virol.72,138–142(2004).
71. Wei,C.J.etal.Cross-neutralizationof1918and2009influenzaviruses:roleof
glycansinviralevolutionandvaccinedesign.Sci.Transl.Med.2,24ra21(2010).
72. An, Y. et al. N-glycosylation of seasonal influenza vaccine hemagglutinins:
implicationforpotencytestingandimmuneprocessing.JVirol.https://doi.org/